Jason Levy, DO
Urology · Baltimore, MDNPI 1437505518
Payments from drug & device makers
What this record shows
This record is dominated by grants: $50,000 of the $55,404 with a category attached, or 90.2%. Boston Scientific accounts for 94.3% of it on its own, with 31 other manufacturers making up the rest. Reporting peaked in 2021 at $51,446 and has fallen 98.3% since, to $850 in 2025. Among urology clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 89 payments — averaging $622.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$52K
- Coloplast$719
- EDAP Technomed Inc$714
- Photocure Inc$301
- Sumitomo Pharma America, Inc.$227
- Astellas Pharma US Inc$115
- plus $1K from 26 others
What the payments were for
- Grants$50,00090%
- Travel & lodging$7101%
- Food & beverage$4,5138%
- Education$1810%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 29 | $52,269 |
| Coloplast | 8 | $719 |
| EDAP Technomed Inc | 3 | $714 |
| Photocure Inc | 3 | $301 |
| Sumitomo Pharma America, Inc. | 9 | $227 |
| Astellas Pharma US Inc | 1 | $115 |
| Blue Earth Diagnostics | 1 | $115 |
| Endo Pharmaceuticals Inc. | 3 | $97 |
| Janssen Scientific Affairs, LLC | 1 | $92 |
| Johnson & Johnson | 1 | $85 |
| Myriad Genetic Laboratories, Inc. | 5 | $83 |
| AbbVie | 3 | $79 |
| Laborie Medical Technologies Corp. | 2 | $64 |
| Endo USA, Inc. | 2 | $48 |
| Novartis | 1 | $33 |
| Biogen | 1 | $28 |
| Innovation Technologies Inc | 1 | $27 |
| Caris MPI, Inc. | 1 | $25 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $24 |
| Calyxo, Inc. | 1 | $23 |
| Teleflex LLC | 1 | $23 |
| Olympus America Inc. | 1 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $23 |
| Ferring Pharmaceuticals Inc. | 1 | $22 |
| Sun Pharmaceutical Industries Inc. | 1 | $22 |
| Dendreon Pharmaceuticals LLC | 1 | $22 |
| Tolmar, Inc. | 1 | $21 |
| Procept Biorobotics Corporation | 1 | $20 |
| Profound Medical Corp. | 1 | $19 |
| Medtronic | 1 | $15 |
| Foundation Medicine, Inc. | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL ERECTILE DYSFUNCTION$50,137
- AMS 700 CXR RTE KIT$635
- TITAN$504
- Cysview$279
- AMS 700$263
- LithoVue$233
- Axumin$115
How this compares
$55,404 in reported general payments places this provider in the 90th percentile of 274 urology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 81 | $65,398 |
| GemtesaVibegron | 11 | $12,501 |
| Mirabegron ErMirabegron | 11 | $3,178 |
| Tamsulosin Hcl | 147 | $1,708 |
| Finasteride | 60 | $769 |
| Oxybutynin Chloride ErOxybutynin Chloride | 18 | $207 |
| Levofloxacin | 24 | $80 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $115 | $65,39881 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $227 | $12,50111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 274 urology providers in Maryland.
Other urology in Baltimore
- Benjamin LowentrittBaltimore$549K
- Amin HeratiBaltimore$160K
- Max KatesBaltimore$139K
- Arthur BurnettBaltimore$132K
- Aaron WeinbergBaltimore$106K
- Brian MatlagaBaltimore$99K
- Ronald TutroneBaltimore$89K
- Jared WinokerBaltimore$62K
- Arvin GeorgeBaltimore$46K
- Christian PavlovichBaltimore$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.